We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

3 hedge funds and large institutions have $177K invested in Progenics Pharmaceuticals Inc in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 126 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 129 → 3 (-126)

100% less capital invested

Capital invested by funds: $222M → $177K (-$222M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 126

Holders
3
Holders Change
-126
Holders Change %
-97.67%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
126
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$52.6M
2
FCM
Farallon Capital Management
California
-$31.4M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$21.8M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$20.3M
5
State Street
State Street
Massachusetts
-$17.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
1
Everence Capital Management
Indiana
$123K – – –
New York State Teachers Retirement System (NYSTRS)
2
New York State Teachers Retirement System (NYSTRS)
New York
$52K – – –
Daiwa Securities Group
3
Daiwa Securities Group
Japan
$2K – – –
BlackRock
4
BlackRock
New York
– -$52.6M -13,850,498 Closed
FCM
5
Farallon Capital Management
California
– -$31.4M -8,250,000 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$21.8M -5,745,266 Closed
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
– -$20.3M -5,342,927 Closed
State Street
8
State Street
Massachusetts
– -$17.6M -4,635,469 Closed
Geode Capital Management
9
Geode Capital Management
Massachusetts
– -$4.75M -1,249,005 Closed
AllianceBernstein
10
AllianceBernstein
Tennessee
– -$4.73M -1,244,815 Closed
Northern Trust
11
Northern Trust
Illinois
– -$4.25M -1,118,652 Closed
TA
12
Tamarack Advisers
California
– -$4.18M -1,100,000 Closed
Bank of New York Mellon
13
Bank of New York Mellon
New York
– -$3.53M -928,279 Closed
N
14
Nuveen
North Carolina
– -$3.48M -915,934 Closed
WAM
15
Wolverine Asset Management
Illinois
– -$3.24M -853,416 Closed
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
– -$3.18M -837,153 Closed
YCM
17
Yakira Capital Management
Connecticut
– -$3.14M -825,438 Closed
BCM
18
Beryl Capital Management
California
– -$2.71M -714,084 Closed
Morgan Stanley
19
Morgan Stanley
New York
– -$2.55M -670,371 Closed
Principal Financial Group
20
Principal Financial Group
Iowa
– -$2.53M -666,732 Closed
Charles Schwab
21
Charles Schwab
California
– -$2.07M -543,870 Closed
IA
22
IndexIQ Advisors
New York
– -$1.89M -496,281 Closed
Invesco
23
Invesco
Georgia
– -$1.75M -459,930 Closed
NAM
24
Nexpoint Asset Management
Texas
– -$1.71M -450,925 Closed
VI
25
Versor Investments
New York
– -$1.65M -433,471 Closed
1
2 3 4 5

PGNX Hedge Fund Activity: Q2 2020 in Review

3 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2020, worth a combined $177K — down 100% from $222M a quarter earlier.

Sellers outnumbered buyers: 126 funds closed out of PGNX and 0 opened new positions — a net loss of 126 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $52.6M sold.

  • 3 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2020, down from 129 in Q1 2020.
  • Funds reported $177K of Progenics Pharmaceuticals Inc stock for Q2 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2020 and 126 closed out, a net change of -126 holders.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2020 was BlackRock, an estimated $52.6M sold.

Based on aggregated 13F filings for Q2 2020.